NCT06162169

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

A Single-center, Non-randomized, Open-lable, Self-controlled Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Allist Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole， rifampicin， and omeprazole in healthy subjects.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	JAB-21822	JAB-21822 was administered orally
DRUG	Itraconazole	Itraconazole was administered orally
DRUG	Omeprazole	Omeprazole was administered orally
DRUG	Midazolam , Rosuvastatin calcium and digoxin	Midazolam , Rosuvastatin calcium and digoxin was administered orally
DRUG	Rifampicin	Rifampicin was administered orally

Timeline

• Start date: 2023-11-25
• Primary completion: 2024-02-20
• Completion: 2024-02-20
• First posted: 2023-12-08
• Last updated: 2025-04-04

Locations

1 site across 1 country: China